eSubmissions | TGA Australia

Stage 1 of the transition to eCTD-only has just started for all regulatory submissions in Australia.

Stage 1 of the transition to eCTD-only has just started for all regulatory submissions in Australia.
November 2, 2021

From 1 November 2021, the Australian Therapeutic Goods Administration (TGA) begins a staged transition to Electronic Common Technical Document- only for all prescription medicines.

Stage 1 of the transition to eCTD-only has just started for all regulatory submissions in Australia. From this date, the following drug applications must be submitted to the Therapeutic Goods Administration (TGA) using the eCTD:

  • New Chemical Entity Medicine (Type A)
  • New Biological Entity Medicine (Type A)
  • New Biosimilar Medicine (Type A)
  • New Combination Medicine (Type B)

Although the majority of the applications of stage 1 are already provided to TGA within eCTD format, requests for exemptions will be assessed by the TGA on a case-by-case basis.

For further information you can contact us at: ectd@asphalion.com

 

Search News & Events

  • Filter by category

Share

Related news and events

NEW | User Acceptance Testing (UAT) phase

Asphalion Expert Beatriz Ugalde Dionicio has been selected by the European Medicines Agency (EMA) to participate in the Product Management Service (PMS) Product User Interface

eCTD transmissions | Switzerland

Discover how Asphalion and Extedo can help you with your eSubmissions in Switzerland! Have a look at this infographic with the summary updates in terms

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting